This study will be a two-arm prospective 1:1 randomised controlled trial comparing:
Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART
preferably including raltegravir (cART) plus ChAdV63.HIVconsv (ChAd) prime and MVA.HIVconsv
(MVA) boost vaccines; followed by a 28-day course of vorinostat (10 doses in total).
We hypothesise that this intervention in primary HIV infection will confer a significant
reduction in the latent HIV reservoir when compared with cART alone.
.
Phase:
Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborators:
Brighton and Sussex University Hospitals NHS Trust Central and North West London NHS Foundation Trust Chelsea and Westminster NHS Foundation Trust Guy's and St Thomas' NHS Foundation Trust Medical Research Council Royal Free Hospital NHS Foundation Trust University of Cambridge University of Oxford